Viome Life Sciences
We're on a mission to decode human biology in order to prevent and reverse chronic diseases, cancers, and aging.
We're on a mission to decode human biology in order to prevent and reverse chronic diseases, cancers, and aging.
Viome Life Sciences, founded in 2016, is dedicated to decoding human biology to prevent and reverse chronic diseases, cancers, and aging. The company's Consumer Services (VIOME) offers a direct-to-consumer healthcare test analyzing microbial and human gene expressions utilizing proprietary technology exclusively licensed from Los Alamos National Lab. This provides individuals with health insights and personalized nutrition plans. Viome's Health Sciences division uses state-of-the-art artificial intelligence to analyze data from the world's largest gene expression database to identify root causes of diseases and develop precision therapeutics. The company's focus includes prediction, early diagnostics, prognostics, and precision therapeutics, leveraging advanced AI methods to discover biomarkers, diagnose conditions, develop companion diagnostics, and target the root cause of diseases. Viome recently received a venture round investment on 20 December 2022 from SquareOne Capital. Viome operates from the United States and aims to make illness optional through its innovative approach to personalized healthcare.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
20 Dec 2022 |
We care about your data, and we'd love to use cookies make your experience better.
